CYP19A1 and breast carcinoma: One of the major standard-of-care therapeutics for the treatment of breast cancer is estrogen deprivation therapy, most commonly tamoxifen, for pre-menopausal breast cancer patients, or an aromatase inhibitor for post-menopausal patients [1].